BCRX
BioCryst Pharmaceuticals Inc
8.60$
+0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 65.3% | 53.0% | 74.6% | 70.3% | 77.9% | 93.8% | 96.7% | 96.3% | 93.9% | 95.9% | 86.0% | 78.6% | |
| 39.8% | 23.2% | 24.6% | 28.2% | 18.2% | 65.1% | 81.3% | 85.8% | 55.4% | 21.4% | 21.4% | 17.5% | |
| 83.2% | 79.7% | 70.8% | 87.3% | 86.4% | 77.7% | 89.7% | 86.3% | 77.1% | 75.2% | 65.5% | 53.4% | |
| 6.9% | 5.0% | 9.8% | 3.4% | 2.9% | 12.6% | 2.6% | 5.0% | 9.2% | 11.0% | 16.1% | 20.8% | |
| 0.5% | 1.3% | 0.6% | -21.2% | 1.1% | 0.9% | 2.1% | 2.7% | 5.0% | 5.5% | 1.6% | 1.0% | |
| 0.2% | 4.1% | 11.0% | 5.4% | 6.2% | 4.2% | 2.1% | 2.6% | 2.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 44.7% | 61.7% | 98.2% | 53.0% | 66.5% | 78.2% | 105.8% | 118.2% | 153.6% | 188.1% | 197.0% | 123.2% | |
| 42.1% | 51.7% | 60.5% | 42.0% | 47.3% | 52.7% | 31.6% | 17.6% | 19.2% | 29.0% | 32.7% | 38.1% | |
| 21.9% | 22.3% | 31.4% | 19.8% | 23.0% | 22.8% | 9.3% | 0.3% | 0.4% | 0.5% | 7.2% | 0.3% | |
| 2.1% | 7.5% | 4.8% | 3.6% | 5.3% | 8.0% | 5.6% | 4.7% | 2.6% | 4.0% | 2.4% | 3.1% | |
| 0.0% | 1.9% | 25.4% | 9.4% | 17.3% | 23.6% | 35.8% | 99.5% | 133.3% | 156.9% | 162.3% | 83.1% | |
| -341.8% | -410.2% | -630.0% | -354.5% | -498.5% | 21.8% | -5.8% | -18.2% | -53.6% | -88.1% | -97.0% | -23.2% | |
| -341.8% | -410.2% | -630.0% | -354.5% | -498.5% | -479.6% | -305.8% | -205.3% | -264.5% | -325.2% | -360.9% | -292.9% | |
| 48.8% | 58.5% | 82.0% | 47.4% | 70.3% | 66.0% | 50.0% | 30.5% | 33.8% | 37.2% | 42.1% | 42.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.